Wang Cong, Chen Cuilan, Chen Xiaoying, Luo Jie, Su Yuting, Liu Xia, Yin Fuqiang
Life Sciences Institute, Guangxi Medical University, Nanning, China.
Key Laboratory of Longevity and Ageing-Related Disease of Chinese Ministry of Education, Centre for Translational Medicine and School of Preclinical Medicine, Guangxi Medical University, Nanning, China.
Transl Cancer Res. 2024 Aug 31;13(8):4354-4371. doi: 10.21037/tcr-23-2157. Epub 2024 Aug 6.
Ovarian cancer (OC) is a kind of lethiferous cancer in gynecology, and the development of chemoresistance is the brief reason for treatment failure. The genes which contribute to chemoresistance are often leading to short survival. Thus, this study aims to identify predictive markers for chemoresistance and survival from chemoresistant-related genes.
Coremine was used to retrieve of genes linked to OC chemoresistance. The relationship of genes with patient survival was analyzed in 489 OC patients of The Cancer Genome Atlas (TCGA) cohort, which the subgroup of 90 resistant and 197 sensitive samples was used to determine gene expression. Kaplan-Meier (KM) plotter of 1,816 OC patients with survival data was retrieved for survival analysis. Survival analysis was carried out by the R survival package in R (version 3.3.1). KM and receiver operating characteristic (ROC) curve were respectively used to access the ability of a gene to predict survival and chemoresistance.
In this study, a group of genes potentially linked to OC chemoresistance was identified, which dysregulated in 90 chemoresistant tissues compared with 197 sensitive tissues. Of them, thirteen genes could predict chemoresistance in 1,347 patients, especially , , were excellent for predicting chemoresistance to any drugs, platin and taxane, and for any drugs and platin, and and for taxane. Meanwhile, 44 genes linked to OC chemoresistance could predict short overall survival (OS) and/or disease-free survival (DFS) in 489 OC patients, and 10 of them could predict short OS in large cohort of up to 1,657 patients. Finally, it is noteworthy that was down-regulated in 90 chemoresistant samples, and low expression of the gene predicted chemoresistance in 1,347 patients, short OS and DFS in 489 patients, and short OS and progression-free survival (PFS) in 1,657 patients.
The identified genes specifically the might be potentially used as predictive marker, prognostic marker and therapeutic target in management of OC.
卵巢癌（OC）是妇科一种致死性癌症，化疗耐药的发生是治疗失败的主要原因。导致化疗耐药的基因常致使患者生存期缩短。因此，本研究旨在从化疗耐药相关基因中鉴定出化疗耐药和生存的预测标志物。
利用Coremine检索与OC化疗耐药相关的基因。在癌症基因组图谱（TCGA）队列的489例OC患者中分析基因与患者生存的关系，其中90例耐药样本和197例敏感样本的亚组用于确定基因表达。检索1816例有生存数据的OC患者的Kaplan-Meier（KM）绘图仪进行生存分析。使用R（版本3.3.1）中的R生存包进行生存分析。分别用KM曲线和受试者工作特征（ROC）曲线评估基因预测生存和化疗耐药的能力。
在本研究中，鉴定出一组可能与OC化疗耐药相关的基因，与197例敏感组织相比，这组基因在90例化疗耐药组织中表达失调。其中，13个基因可在1347例患者中预测化疗耐药，尤其是 、 、 对任何药物、铂类和紫杉烷的化疗耐药预测效果极佳， 、 对任何药物和铂类， 、 对紫杉烷。同时，44个与OC化疗耐药相关的基因可在489例OC患者中预测较短的总生存期（OS）和/或无病生存期（DFS），其中10个基因可在多达1657例患者的大型队列中预测较短的OS。最后，值得注意的是， 在90例化疗耐药样本中表达下调，该基因低表达在1347例患者中预测化疗耐药，在489例患者中预测较短的OS和DFS，在1657例患者中预测较短的OS和无进展生存期（PFS）。
所鉴定的基因，尤其是 ，可能在OC的管理中用作预测标志物、预后标志物和治疗靶点。
